

Supplementary Information

for

Asymmetric Boron Conjugate Addition to α,β -Unsaturated Carbonyl Compounds Catalyzed by CuOTf/Josiphos under Non-Alkaline Condition

Jian-Bo Xie,^a Siqi Lin,^a Jian Luo,^a Jianbin Wu,^a Timothy R. Winn,^a and Guigen Li*^{a,b}

^aDepartment of Chemistry and Biochemistry, Texas Tech University, Lubbock, Texas 79409-1061, United States

^bInstitute of Chemistry & BioMedical Sciences (ICBMS), Nanjing University, Nanjing 210093, P. R. China

guigen.li@ttu.edu

Table of Contents

General information.....S-2

General procedure for asymmetric boron conjugate addition.....S-2–S-10

NMR spectra of new compounds.....S-10–S-15

HPLC charts for products.....S-15–S-30

General Information

All commercially available chemicals including solvents, unless otherwise mentioned, were used without purification. DCM was distilled from CaH₂. Toluene and THF were distilled from Na/benzophenone. MeOH, EtOH, ⁱPrOH and ^tBuOH were dried by 4Å Molecular Sieves. B₂Pin₂ was purchased from Frontier Scientific. (CuOTf)₂.Benzene was purchased from Alfa Asear. The Josiphos ligands were purchased from Strem Chemicals Inc. HPLC analyses were performed using a Waters Delta 600 instrument with a Waters 2996 PDA detector. All the glasswares used were dried overnight at 110 °C. The NMR spectra were recorded at 400, 100, and 162 MHz for ¹H, ¹³C, and ³¹P, respectively with a JEOL ECS 400 MHz Spectrometer. Optical rotations were determined using an Autopol® IV automatic polarimeter.

General procedure for asymmetric boron conjugate addition

To a dry and clean 10 mL schlenk tube was added (CuOTf)₂.Benzene (1.2 mg, 2.4 × 10⁻³ mmol, 2.5 mol%) and chiral ligand (5.8 × 10⁻³ mmol, 6.0 mol%). Then replace the atmosphere by Argon for three times. Toluene (2.0 mL) was added and the mixture was stirred for 24 hrs. Then the α,β-unsaturated carbonyl compound and B₂Pin₂ in 0.5 mL toluene was added by syringe, followed by addition of MeOH (100 μL). The reaction was stirred vigorously for 48 hrs. The reaction mixture was concentrated in vacuum and analyzed with ¹H NMR. The crude product was purified by flash column chromatography eluted by ethyl acetate / hexanes (v/v = 1/10 to 1/15). The product obtained was checked by HPLC analysis.

(R)-1,3-Diphenyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)propan-1-one (**2a**)

90% yield, 91% ee. ^1H NMR (400 MHz, CDCl_3) δ 1.16 (CH_3 , s, 6H), 1.24 (CH_3 , s, 6H), 2.79 (CH , dd, $J = 5.0$ Hz, $J = 10.6$ Hz, 1H), 3.42 (CH_2 , dd, $J = 5.0$ Hz, $J = 18.3$ Hz, 1H), 3.55 (CH_2 , dd, $J = 10.6$ Hz, $J = 18.3$ Hz, 1H), 7.15–7.54 (Ar-H, m, 8H), 7.95 (Ar-H, d, $J = 7.8$ Hz, 2H). $[\alpha]_D^{25} -17.2$ (c 0.50, CHCl_3). The enantiomeric excess was determined by HPLC with a Chiralpak AD column: eluent, hexanes/ $i\text{PrOH}$ (98:2); flow rate = 1.0 mL/min; tR = 15.5 min (minor); tR = 22.8 min (major).

(R)-3-(2-Chlorophenyl)-1-phenyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)propan-1-one (**2b**)


24% yield, 93% ee. ^1H NMR (400 MHz, CDCl_3) δ 1.22 (CH_3 , s, 6H), 1.27 (CH_3 , s, 6H), 3.27–3.32 (CH , m, 1H), 3.45–3.48 (CH_2 , m, 2H), 7.06–7.55 (Ar-H, m, 7H), 7.94 (Ar-H, d, $J = 7.3$ Hz, 2H). $[\alpha]_D^{25} +17.5$ (c 0.20, CHCl_3). The enantiomeric excess was determined by HPLC with a Chiralpak AD column: eluent, hexanes/ $i\text{PrOH}$ (98:2); flow rate = 1.0 mL/min; tR = 12.8 min (minor); tR = 14.6 min (major).

3-(3-Nitrophenyl)-1-phenyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)propan-1-one (**2c**)


95% yield, 95% ee. ^1H NMR (400 MHz, CDCl_3) δ 1.17 (CH_3 , s, 6H), 1.23 (CH_3 , s, 6H), 2.92 (CH , dd, $J = 5.5$ Hz,

J = 9.6 Hz, 1H), 3.47 (CH₂, dd, *J* = 5.5 Hz, *J* = 12.4 Hz, 1H), 3.57 (CH₂, dd, *J* = 9.6 Hz, *J* = 12.4 Hz, 1H), 7.40–7.66 (Ar-H, m, 4H), 7.96–8.04 (Ar-H, m, 3H), 8.19 (Ar-H, t, *J* = 1.8 Hz, 1H). ¹³C NMR (100 MHz, CDCl₃) δ 24.6, 42.6, 83.9, 120.9, 123.2, 128.2, 128.7, 129.3, 133.3, 135.1, 136.5, 144.4, 148.5, 199.0. HRMS (ESI) m/z calcd for C₂₁H₂₅BNO₅ ([M + H]⁺): 382.1820; found: 382.1817. [α]_D²⁵ +3.4 (*c* 0.90, CHCl₃). The enantiomeric excess was determined by HPLC with a Chiralpak AD column: eluent, hexanes/*i*PrOH (90:10); flow rate = 1.0 mL/min; tR = 17.8 min (minor); tR = 23.1 min (major).

(*R*)-3-(4-Methoxyphenyl)-1-phenyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)propan-1-one (**2d**)


 89% yield, 93% ee. ¹H NMR (400 MHz, CDCl₃) δ 1.16 (CH₃, s, 6H), 1.23 (CH₃, s, 6H), 2.73 (CH, dd, *J* = 5.0 Hz, *J* = 11.0 Hz, 1H), 3.37 (CH₂, dd, *J* = 5.0 Hz, *J* = 18.3 Hz, 1H), 3.49 (CH₂, dd, *J* = 11.0 Hz, *J* = 18.3 Hz, 1H), 3.77 (OMe, s, 3H), 6.80–7.95 (Ar-H, m, 9H). [α]_D²⁵ −21.5 (*c* 1.00, CHCl₃). The enantiomeric excess was determined by HPLC with a Chiralpak AD column: eluent, hexanes/*i*PrOH (98:2); flow rate = 1.0 mL/min; tR = 24.8 min (minor); tR = 38.9 min (major).

3-(4-Fluorophenyl)-1-phenyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)propan-1-one (**2e**)

 96% yield, 95% ee. ¹H NMR (400 MHz, CDCl₃) δ 1.15


(CH₃, s, 6H), 1.22 (CH₃, s, 6H), 2.76 (CH, dd, *J* = 5.0 Hz, *J* = 10.5 Hz, 1H), 3.38 (CH₂, dd, *J* = 5.0 Hz, *J* = 17.9 Hz, 1H), 3.49 (CH₂, dd, *J* = 10.5 Hz, *J* = 17.9 Hz, 1H), 6.92–7.55 (Ar-H, m, 7H), 7.94 (ArH, d, *J* = 7.3 Hz, 1H). ¹³C NMR (100 MHz, CDCl₃) δ 24.6, 24.6, 43.4, 83.5, 115.2, 115.4, 128.1, 128.6, 129.7, 129.8, 133.1, 136.8, 137.6, 137.6, 160.0, 162.5, 199.6. HRMS (ESI) m/z calcd for C₂₁H₂₅BFO₃ ([M + H]⁺): 355.1875; found: 355.1872. [α]_D²⁵ –15.1 (*c* 0.90, CHCl₃). The enantiomeric excess was determined by HPLC with a Chiralpak AD column: eluent, hexanes/ⁱPrOH (98:2); flow rate = 1.0 mL/min; tR = 17.0 min (minor); tR = 24.6 min (major).

(*R*)-3-(4-Chlorophenyl)-1-phenyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)propan-1-one (**2f**)



98% yield, 95% ee. ¹H NMR (400 MHz, CDCl₃) δ 1.16 (CH₃, s, 6H), 1.23 (CH₃, s, 6H), 2.77 (CH, dd, *J* = 5.5 Hz, *J* = 10.6 Hz, 1H), 3.42 (CH₂, dd, *J* = 5.5 Hz, *J* = 18.4 Hz, 1H), 3.50 (CH₂, dd, *J* = 10.6 Hz, *J* = 18.4 Hz, 1H), 7.13–7.56 (Ar-H, m, 7H), 7.95 (ArH, d, *J* = 7.3 Hz, 1H). [α]_D²⁵ –30.5 (*c* 1.00, CHCl₃). The enantiomeric excess was determined by HPLC with a Chiralpak AD column: eluent, hexanes/ⁱPrOH (98:2); flow rate = 1.0 mL/min; tR = 18.4 min (minor); tR = 27.9 min (major).


(*R*)-1-(4-Methoxyphenyl)-3-phenyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)propan-1-one (**2g**)




98% yield, 90% ee. ¹H NMR (400 MHz, CDCl₃) δ 1.15 (S-5)

(CH₃, s, 6H), 1.24 (CH₃, s, 6H), 2.76 (CH, dd, *J* = 5.5 Hz, *J* = 11.0 Hz, 1H), 3.37 (CH₂, dd, *J* = 5.5 Hz, *J* = 18.3 Hz, 1H), 3.48 (CH₂, dd, *J* = 11.0 Hz, *J* = 18.3 Hz, 1H), 3.84 (OMe, s, 3H), 6.89 (Ar-H, d, *J* = 9.2 Hz, 2H), 7.12–7.30 (Ar-H, m, 5H), 7.93–7.56 (Ar-H, d, *J* = 9.2 Hz, 2H). [α]_D²⁵ –12.5 (*c* 1.00, CHCl₃). The enantiomeric excess was determined by HPLC with a Chiraldak AD column: eluent, hexanes/ⁱPrOH (98:2); flow rate = 1.0 mL/min; tR = 34.3 min (minor); tR = 50.8 min (major).

(R)-1-(4-Fluorophenyl)-3-phenyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)propan-1-one (2h)

 96% yield, 95% ee. ¹H NMR (400 MHz, CDCl₃) δ 1.15 (CH₃, s, 6H), 1.23 (CH₃, s, 6H), 2.78 (CH, dd, *J* = 5.0 Hz, *J* = 11.0 Hz, 1H), 3.37 (CH₂, dd, *J* = 5.0 Hz, *J* = 18.3 Hz, 1H), 3.51 (CH₂, dd, *J* = 11.0 Hz, *J* = 18.3 Hz, 1H), 7.08–7.99 (Ar-H, m, 9H). [α]_D²⁵ –23.4 (*c* 1.00, CHCl₃). The enantiomeric excess was determined by HPLC with a Chiraldak AD column: eluent, hexanes/ⁱPrOH (98:2); flow rate = 1.0 mL/min; tR = 16.5 min (minor); tR = 22.6 min (major).


1-(4-Chlorophenyl)-3-phenyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)propan-1-one (2i)

 86% yield, 92% ee. ¹H NMR (400 MHz, CDCl₃) δ 1.16 (CH₃, s, 6H), 1.25 (CH₃, s, 6H), 2.79 (CH, dd, *J* = 5.0 Hz, *J* = 10.7 Hz, 1H), 3.36 (CH₂, dd, *J* = 5.0 Hz, *J* = 18.3 Hz, 1H), 3.51 (CH₂, dd, *J* = 10.7


Hz, $J = 18.3$ Hz, 1H), 7.13–7.41 (Ar-H, m, 7H), 7.89 (Ar-H, d, $J = 8.2$ Hz, 2H). ^{13}C NMR (100 MHz, CDCl_3) δ 24.6, 24.6, 43.3, 83.5, 125.8, 128.4, 128.6, 128.9, 129.6, 135.2, 139.4, 141.8, 198.6. HRMS (ESI) m/z calcd for $\text{C}_{21}\text{H}_{25}\text{BClO}_3$ ($[\text{M} + \text{H}]^+$): 371.1580; found: 371.1577. $[\alpha]_D^{25} -15.0$ (c 0.60, CHCl_3). The enantiomeric excess was determined by HPLC with a Chiralpak AD column: eluent, hexanes/ $i\text{PrOH}$ (98:2); flow rate = 1.0 mL/min; tR = 18.0 min (minor); tR = 27.5 min (major).

1,3-Bis(4-fluorophenyl)-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)propan-1-one


(2j)

 95% yield, 94% ee. ^1H NMR (400 MHz, CDCl_3) δ 1.15 (CH₃, s, 6H), 1.22 (CH₃, s, 6H), 2.75 (CH, dd, $J = 5.0$ Hz, $J = 10.5$ Hz, 1H), 3.34 (CH₂, dd, $J = 5.0$ Hz, $J = 17.9$ Hz, 1H), 3.45 (CH₂, dd, $J = 10.5$ Hz, $J = 17.9$ Hz, 1H), 6.92–7.25 (Ar-H, m, 6H), 7.94–7.98 (Ar-H, m, 2H). ^{13}C NMR (100 MHz, CDCl_3) δ 24.6, 24.6, 43.2, 83.6, 115.2, 115.5, 115.6, 115.8, 129.7, 129.8, 130.7, 130.8, 133.2, 133.2, 137.5, 137.5, 160.0, 162.5, 164.5, 167.1, 198.0. HRMS (ESI) m/z calcd for $\text{C}_{21}\text{H}_{24}\text{BF}_2\text{O}_3$ ($[\text{M} + \text{H}]^+$): 373.1781; found: 373.1777. $[\alpha]_D^{25} -16.3$ (c 0.60, CHCl_3). The enantiomeric excess was determined by HPLC with a Chiralpak AD column: eluent, hexanes/ $i\text{PrOH}$ (98:2); flow rate = 1.0 mL/min; tR = 19.5 min (minor); tR = 22.3 min (major).


3-(2,4-Dimethoxyphenyl)-1-(4-fluorophenyl)-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)propan-1-one (**2k**)


 50% yield, 82% ee. ^1H NMR (400 MHz, CDCl_3) δ 1.18 (CH_3 , s, 6H), 1.24 (CH_3 , s, 6H), 2.99 (CH , dd, $J = 6.4$ Hz, $J = 8.2$ Hz, 1H), 3.22 (CH_2 , dd, $J = 6.4$ Hz, $J = 17.9$ Hz, 1H), 3.37 (CH_2 , dd, $J = 8.2$ Hz, $J = 17.9$ Hz, 1H), 3.74 (OCH_3 , s, 3H), 3.75 (OCH_3 , s, 3H), 6.36–6.39 (Ar-H, m, 2H), 7.02–7.16 (Ar-H, m, 3H), 7.90–7.94 (Ar-H, m, 3H). ^{13}C NMR (100 MHz, CDCl_3) δ 24.7, 24.9, 41.5, 55.2, 55.3, 83.3, 115.3, 115.5, 123.1, 130.6, 130.7, 130.8, 133.8, 158.0, 159.1, 164.3, 166.8, 198.7. HRMS (ESI) m/z calcd for $\text{C}_{23}\text{H}_{29}\text{BFO}_5$ ($[\text{M} + \text{H}]^+$): 415.2087; found: 415.2079. $[\alpha]_D^{25} -30.9$ (c 0.75, CHCl_3). The enantiomeric excess was determined by HPLC with a Chiralpak OD-H column: eluent, hexanes/ $i\text{PrOH}$ (90:10); flow rate = 1.0 mL/min; tR = 11.9 min (major); tR = 14.7 min (minor).

(R)-4-Phenyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)butan-2-one (2l)



 76% yield, 72% ee. ^1H NMR (400 MHz, CDCl_3) δ 1.14 (CH_3 , s, 6H), 1.21 (CH_3 , s, 6H), 2.12 (CH_3 , s, 3H), 2.62 (CH , dd, $J = 5.5$ Hz, $J = 10.5$ Hz, 1H), 2.82 (CH , dd, $J = 5.5$ Hz, $J = 18.3$ Hz, 1H), 3.02 (CH , dd, $J = 10.5$ Hz, $J = 18.3$ Hz, 1H), 7.10–7.25 (Ar-H, m, 5H). $[\alpha]_D^{25} -8.8$ (c 0.50, CHCl_3). The enantiomeric excess was determined by HPLC with a Chiralpak AD column: eluent, hexanes/ $i\text{PrOH}$ (98:2); flow rate = 0.5 mL/min; tR = 27.7 min (minor); tR = 28.9 min (major).

(S)-1-Phenyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)butan-1-one (2m)




The enantiomeric excess was determined by HPLC with a Chiralpak AD column: eluent, hexanes/ $i\text{PrOH}$ (98:2); flow rate = 1.0 mL/min; tR = 11.2 min (minor); tR = 14.8 min (major).

(R)-Benzyl 3-phenyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)propanoate (2n)




(S)-Benzyl 3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)butanoate (2o)




AD column: eluent, hexanes/ⁱPrOH (98:2); flow rate = 1.0 mL/min; tR = 10.4 min (minor); tR = 11.0 min (major).


NMR spectra of new compounds


3-(3-Nitrophenyl)-1-phenyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)propan-1-one (**2c**)







3-(4-Fluorophenyl)-1-phenyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)propan-1-one (**2e**)







1-(4-Chlorophenyl)-3-phenyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)propan-1-one (2i)







1,3-Bis(4-fluorophenyl)-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)propan-1-one
(2j)






3-(2,4-Dimethoxyphenyl)-1-(4-fluorophenyl)-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)propan-1-one (**2k**)






HPLC charts for products


(*R*)-1,3-Diphenyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)propan-1-one (**2a**)




Name	Retention Time (min)	Area ($\mu\text{V}^*\text{sec}$)	% Area	Height (μV)	Int Type
1	15.905	22259391	49.88	508688	BV
2	24.592	22370077	50.12	470366	BB





(*R*)-3-(2-Chlorophenyl)-1-phenyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)prop-1-one (**2b**)






3-(3-Nitrophenyl)-1-phenyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)propan-1-one (2e)






	Name	Retention Time (min)	Area ($\mu\text{V}^*\text{sec}$)	% Area	Height (μV)	Int Type
1		15.992	2012401	2.55	82781	VB
2		20.939	76924745	97.45	2469924	BB

(*R*)-3-(4-Methoxyphenyl)-1-phenyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)propan-1-one (**2d**)




	Name	Retention Time (min)	Area ($\mu\text{V}^*\text{sec}$)	% Area	Height (μV)	Int Type
1		24.813	25972993	49.79	727216	VB
2		38.938	26187004	50.21	468055	BB




Name	Retention Time (min)	Area ($\mu\text{V}^*\text{sec}$)	% Area	Height (μV)	Int Type
1	22.687	3969531	3.75	116070	BB
2	35.262	101810025	96.25	1900574	BB


3-(4-Fluorophenyl)-1-phenyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)propan-1-one (**2e**)




Name	Retention Time (min)	Area ($\mu\text{V}^*\text{sec}$)	% Area	Height (μV)	Int Type
1	16.808	12855211	49.21	524323	BB
2	24.582	13269630	50.79	383703	BB




(R)-3-(4-Chlorophenyl)-1-phenyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)propan-1-one (**2f**)




Name	Retention Time (min)	Area ($\mu\text{V}^*\text{sec}$)	% Area	Height (μV)	Int Type
1	18.236	20909745	49.98	795211	VV
2	27.830	20925973	50.02	527997	BB




(R)-1-(4-Methoxyphenyl)-3-phenyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)propan-1-one (**2g**)






	Name	Retention Time (min)	Area ($\mu\text{V}^*\text{sec}$)	% Area	Height (μV)	Int Type
1		34.343	3101980	5.11	56038	BB
2		50.755	57579841	94.89	755469	BB

(R)-1-(4-Fluorophenyl)-3-phenyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)propan-1-one (**2h**)




	Name	Retention Time (min)	Area ($\mu\text{V}^*\text{sec}$)	% Area	Height (μV)	Int Type
1		16.572	20952556	49.76	928663	BB
2		22.832	21157672	50.24	684455	BB




Name	Retention Time (min)	Area ($\mu\text{V}^*\text{sec}$)	% Area	Height (μV)	Int Type
1	16.523	1203248	2.75	54506	BB
2	22.649	42512837	97.25	1376385	BB


1-(4-Chlorophenyl)-3-phenyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)propan-1-one (**2i**)




Name	Retention Time (min)	Area ($\mu\text{V}^*\text{sec}$)	% Area	Height (μV)	Int Type
1	17.988	4418405	50.10	174171	BB
2	27.297	4400048	49.90	114134	BB




1,3-Bis(4-fluorophenyl)-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)propan-1-one
(2j)






Name	Retention Time (min)	Area ($\mu\text{V}^*\text{sec}$)	% Area	Height (μV)	Int Type
1	19.484	2472245	3.05	88235	BV
2	26.261	78511721	96.95	2024095	VB

3-(2,4-Dimethoxyphenyl)-1-(4-fluorophenyl)-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolane-2-yl)propan-1-one (**2k**)




Name	Retention Time (min)	Area ($\mu\text{V}^*\text{sec}$)	% Area	Height (μV)	Int Type
1	12.094	4859689	50.16	169687	VB
2	15.027	4829034	49.84	134083	BB




Name	Retention Time (min)	Area ($\mu\text{V}^*\text{sec}$)	% Area	Height (μV)	Int Type
1	11.868	13567813	90.79	451963	VV
2	14.692	1376654	9.21	36618	VV

(R)-4-Phenyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)butan-2-one (**2l**)




Name	Retention Time (min)	Area ($\mu\text{V}^*\text{sec}$)	% Area	Height (μV)	Int Type
1	27.588	49059649	49.70	1298916	VV
2	28.757	49652632	50.30	1264155	VV




Name	Retention Time (min)	Area ($\mu\text{V}^*\text{sec}$)	% Area	Height (μV)	Int Type
1	27.737	3309242	13.90	91657	BV
2	28.916	20498869	86.10	529699	VV

(S)-1-Phenyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)butan-1-one (**2m**)




Name	Retention Time (min)	Area ($\mu\text{V}^*\text{sec}$)	% Area	Height (μV)	Int Type
1	11.177	4667514	50.33	291475	BV
2	14.897	4607023	49.67	227222	BB




Name	Retention Time (min)	Area ($\mu\text{V}^*\text{sec}$)	% Area	Height (μV)	Int Type
1	11.150	881765	2.25	54147	BB
2	14.774	38339979	97.75	1853989	VV


(R)-Benzyl 3-phenyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)propanoate (2n)




Name	Retention Time (min)	Area ($\mu\text{V}^*\text{sec}$)	% Area	Height (μV)	Int Type
1	16.746	51300782	48.26	2076744	VV
2	17.892	54990007	51.74	2070962	VB



(S)-Benzyl 3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)butanoate (**2o**)





	Name	Retention Time (min)	Area ($\mu\text{V}^*\text{sec}$)	% Area	Height (μV)	Int Type
1		10.438	472557	5.95	33180	BV
2		10.973	7466722	94.05	491107	VV